Regañón E, Vila V, Aznar J, Laiz B
Research Center, La Fe Hospital, Valencia, Spain.
Clin Chim Acta. 1989 Sep 15;184(1):7-17. doi: 10.1016/0009-8981(89)90252-0.
Different fibrinogen species were examined in normal plasma following urokinase treatment, in isolated high molecular weight fibrinogen treated with plasmin and in plasma samples from patients with acute myocardial infarction receiving thrombolytic therapy. In normal plasmas two main fibrinogen species (Mr = 340,000 and Mr = 320,000) and an intermediate fragment (Mr = 330,000) were observed. The 340,000 fibrinogen was the most sensitive to degradation; it gave rise to 330,000 and 320,000 species. Degradation of isolated 340,000 fibrinogen was similar to plasma fibrinogen degradation. After thrombolytic therapy in acute myocardial infarction patients, when the plasma fibrinogen decreased near to zero, the new synthesized fibrinogen was 340,000 form. 'In vivo' conversion of 340,000 to 320,000 fibrinogen, associated with the transitory 330,000 form, was observed. The coagulation study of plasma fibrinogen showed that when Mr 340,000 fibrinogen decreased (40%), the gelation rate decreased and lag time increased drastically. The high 340,000 fibrinogen content found in acute myocardial infarction patients gave rise to the hypercoagulable state.
对尿激酶处理后的正常血浆、经纤溶酶处理的分离的高分子量纤维蛋白原以及接受溶栓治疗的急性心肌梗死患者的血浆样本中的不同纤维蛋白原种类进行了检测。在正常血浆中观察到两种主要的纤维蛋白原种类（分子量分别为340,000和320,000）以及一种中间片段（分子量为330,000）。分子量为340,000的纤维蛋白原对降解最为敏感；它会产生分子量为330,000和320,000的种类。分离的分子量为340,000的纤维蛋白原的降解与血浆纤维蛋白原的降解相似。在急性心肌梗死患者接受溶栓治疗后，当血浆纤维蛋白原降至接近零时，新合成的纤维蛋白原为分子量340,000的形式。观察到了分子量为340,000的纤维蛋白原在“体内”转化为分子量为320,000的纤维蛋白原，并伴有短暂的分子量为330,000的形式。血浆纤维蛋白原的凝血研究表明，当分子量为340,000的纤维蛋白原减少（40%）时，凝胶化速率降低，滞后时间大幅增加。急性心肌梗死患者中发现的高含量分子量为340,000的纤维蛋白原导致了高凝状态。
